Quoin Net Income Applicable To Common Shares from 2010 to 2025

QNRX Stock  USD 0.57  0.02  3.39%   
Quoin Pharmaceuticals Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss will likely drop to about -8.9 M in 2025. Net Loss is the net income that remains after preferred dividends have been deducted, available to common shareholders. View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-8.5 M
Current Value
-8.9 M
Quarterly Volatility
5.6 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Quoin Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Quoin Pharmaceuticals' main balance sheet or income statement drivers, such as Selling General Administrative of 4 M, Total Revenue of 0.0 or Other Operating Expenses of 7 M, as well as many indicators such as Dividend Yield of 7.58, Ptb Ratio of 0.85 or Book Value Per Share of 6.87. Quoin financial statements analysis is a perfect complement when working with Quoin Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Quoin Pharmaceuticals Correlation against competitors.

Latest Quoin Pharmaceuticals' Net Income Applicable To Common Shares Growth Pattern

Below is the plot of the Net Income Applicable To Common Shares of Quoin Pharmaceuticals Ltd over the last few years. It is the net income that remains after preferred dividends have been deducted, available to common shareholders. Quoin Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Quoin Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Net Income Applicable To Common Shares10 Years Trend
Slightly volatile
   Net Income Applicable To Common Shares   
       Timeline  

Quoin Net Income Applicable To Common Shares Regression Statistics

Arithmetic Mean(4,717,798)
Geometric Mean2,907,414
Coefficient Of Variation(117.85)
Mean Deviation4,274,550
Median(1,560,401)
Standard Deviation5,560,112
Sample Variance30.9T
Range19.9M
R-Value(0.63)
Mean Square Error20T
R-Squared0.40
Significance0.01
Slope(735,972)
Total Sum of Squares463.7T

Quoin Net Income Applicable To Common Shares History

2025-8.9 M
2024-8.5 M
2022-9.4 M
2021-21.5 M
2020-2.1 M

About Quoin Pharmaceuticals Financial Statements

Quoin Pharmaceuticals investors use historical fundamental indicators, such as Quoin Pharmaceuticals' Net Income Applicable To Common Shares, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Quoin Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-8.5 M-8.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Quoin Stock Analysis

When running Quoin Pharmaceuticals' price analysis, check to measure Quoin Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quoin Pharmaceuticals is operating at the current time. Most of Quoin Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Quoin Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quoin Pharmaceuticals' price. Additionally, you may evaluate how the addition of Quoin Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.